Palisade Bio begins MAD cohorts of Phase Ia/b ulcerative colitis therapy trial
The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.
bovnews4h
Palisade Bio Inc (PALI) Stock: More Resilient Than It Appears
In recent trading, Palisade Bio Inc (PALI) stock price has shown some volatility, fluctuating -17.41% over the last five trades and -6.
Santé log21h
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 ...